Evidence map›Paper›PMID 41195101›Full record

ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025

Linear accelerator selection: impact on feasibility dose-volume histograms and practicality in dose reduction for organs at risk during prostate volumetric-modulated arc therapy.

Motoharu Sasaki, Yuji Nakaguchi, Takeshi Kamomae, Masataka Oita, Hitoshi Ikushima

Abstract read
In one paragraph

Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Motoharu SasakiDepartment of Therapeutic Radiology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Yuji NakaguchiToyo Medic Co., Ltd, Tokyo, Japan.
Takeshi KamomaeRadioisotope Research Center, Nagoya University, Nagoya, Japan.
Masataka OitaFaculty of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan.
Hitoshi IkushimaDepartment of Therapeutic Radiology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The quality of volumetric-modulated arc therapy (VMAT) plans depends on the planner's expertise. A feasibility dose-volume histogram (FDVH) may help reduce planning variability. Materials and methods: This study evaluated the impact of two linear accelerators - Halcyon and TrueBeam - on FDVH in prostate VMAT planning and their effectiveness in reducing doses to organs at risk (OARs). VMAT plans were generated for 30 patients with prostate cancer, with planning target volume excluding the rectum (PTV-R) and OAR contours created by three planners. An FDVH was created, and plans were classified as "difficult" (0 < F ≤ 0.1) based on OAR dose reduction. Results: The D98% and D2% of PTV-R were analyzed, showing that TrueBeam had a higher mean dose at D98% and a lower mean dose at D2% compared to Halcyon, but these differences were not statistically significant (D98%: p = 0.123, D2%: p = 0.167). For the rectum, TrueBeam resulted in significantly lower doses for all dose constraints compared to Halcyon (p < 0.001). In the bladder, TrueBeam showed a significantly lower dose at V40Gy (p < 0.001). The upper limits of feasible F-values were 0.00-0.12 (TrueBeam) and 0.00-0.17 (Halcyon) for the rectum, and 0.01-0.20 (TrueBeam) and 0.00-0.20 (Halcyon) for the bladder, depending on dose parameters. Conclusions: These findings highlight that the choice of the linear accelerator significantly impacts OAR dose reduction. In prostate VMAT, TrueBeam demonstrated superior rectal and bladder dose reduction compared to Halcyon, underscoring the importance of selecting the appropriate device to optimize treatment planning and minimize variability.

Indexed as

feasibility dose-volume histogramPlanIQprostate cancer

Identifiers

PMID41195101
PMCPMC12585118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.